This was the stock's second consecutive day of losses.

Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Oppenheimer reaffirmed its positive stance on Catalyst Pharmaceutical (TADAWUL:2070) Partners (NASDAQ:CPRX), maintaining an ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 11.63% ...

For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.

Shares of Catalyst Pharmaceuticals Inc. CPRX rose 1.32% to $22.21 Monday, on what proved to be an all-around mixed trading ...

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) had its price target raised by HC Wainwright from $30.00 to $35.00 ...

StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy ...

Catalyst Pharmaceuticals, Inc. announced that its sub-licensee, DyDo Pharma, has launched FIRDAPSE® (amifampridine) Tablets 10 mg in Japan, aimed at improving muscle weakness in patients with ...